Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura

获得性血栓性血小板减少性紫癜的新疗法

基本信息

批准号：
8669155
负责人：
X. Long Zheng
金额：
$ 41.45万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-01 至 2015-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8669155
关键词：
Adult Amino Acids Antibodies Attenuated Autoantibodies Autoimmune Process B-Lymphocytes Binding Biochemical Biological Biological Assay Biological Process Blood Circulation Blood Platelets Blood Vessels Cleaved cell Clinical Coupled Deuterium Diagnosis Ectopic Expression Endothelial Cells Engineering Enzymes Epitopes Exhibits Future Goals Hematopoietic stem cells Hemolytic Anemia Hemostatic function Human Hydrogen Immunoglobulin G Injury Laboratories Left Lentivirus Vector Libraries Light Maps Mass Spectrum Analysis Metalloproteases Microfluidics Modeling Modification Molecular Mus Organ failure Pathogenesis Pathogenicity Patients Phage Display Phenotype Plasma Plasma Exchange Platelet Factor 4 Platelet Glycoproteins Play Prevention Property Recombinants Resistance Resolution Role Series Shiga Toxin Site Site-Directed Mutagenesis Structure-Activity Relationship Surface Syndrome Testing Therapeutic Thrombocytopenia Thrombosis Thrombotic Thrombocytopenic Purpura Thrombus Transgenic Organisms Transplantation Variant design effective therapy gain of function human monoclonal antibodies inhibitor/antagonist insight mortality mouse model novel novel strategies novel therapeutics promoter public health relevance reconstitution targeted delivery therapeutic development therapeutic enzyme tool von Willebrand Factor

项目摘要

DESCRIPTION (provided by applicant): Thrombotic thrombocytopenic purpura (TTP) is a fatal syndrome. Acquired TTP is mainly caused by autoantibodies that inhibit ADAMTS13 enzyme. Plasma exchange is the only effective therapy available to date. In Aim1 of this proposal, we will reengineer and characterize a series of novel recombinant ADAMTS13 variants that exhibit increased specific activity, but are resistant to inhibition by autoantibodies from patients with acquired TTP. The completion of this aim will provide novel insights into the structure-function relationship of ADAMTS13 and change how we treat TTP today. In Aim 2, we propose to determine the antigenic binding epitopes at the amino acid resolution using our novel and groundbreaking deuterium exchange coupled with mass spectrometric analysis approaches. In addition, we will determine the pathogenicity of a panel of inhibitory scFV(s) in murine models of arterial thrombosis and TTP established in the laboratory. The information gained from this study may help our understanding of the molecular mechanisms of acquired TTP and the rational designing of novel recombinant ADAMTS13 variants with desired properties (such as resistance to autoantibody inhibition) for future therapy. Finally, in Aim 3, we will test the hypothesis that ectopic expression of wild-type ADAMTS13 and gain-of-function/antibody-resistant ADAMTS13 variants in platelets would target the therapeutic enzyme directly to sites of injury without being inhibited by circulating anti-ADAMTS13 antibodies. Overall, the information obtained from the completion of the proposed study will provide novel insight into the structure-function relationship of ADAMTS13, help our understandings of the mechanisms of acquired TTP, and provide novel tools for potential therapy of such a fatal TTP syndrome.

描述（由申请人提供）：血栓性血小板减少性紫癜（TTP）是致命的综合征。获得的TTP主要是由抑制ADAMTS13酶的自身抗体引起的。血浆交换是迄今为止唯一可用的有效疗法。在该提案的AIM1中，我们将重新设计并表征一系列新型的重组ADAMTS13变体，这些变体具有增加的特异性活性，但对获得的TTP患者的自身抗体抑制具有抗性。这个目标的完成将为ADAMTS13的结构 - 功能关系提供新的见解，并改变我们今天对待TTP的方式。在AIM 2中，我们建议使用我们的新颖和开创性的氘交换以及质谱分析方法来确定氨基酸分辨率的抗原结合表位。此外，我们将确定在实验室中建立的动脉血栓形成和TTP的鼠模型中，一组抑制性SCFV的致病性。从这项研究中获得的信息可能有助于我们理解所获得的TTP的分子机制以及具有所需特性（例如对自身抗体抑制的抗性）的新型重组ADAMTS13变体的合理设计。最后，在AIM 3中，我们将检验以下假设：血小板中野生型ADAMTS13的异位表达和功能获得/抗体抗体的ADAMTS13变体将直接靶向治疗酶，直接靶向受伤部位，而不会受到循环抗ADAMADAMTS13抗体的循环抑制。总体而言，从提议的研究完成中获得的信息将提供有关ADAMTS13的结构功能关系的新见解，有助于我们对获得的TTP机制的理解，并为这种致命的TTP综合征提供潜在治疗的新工具。